Imugene completes $11.1M share placement
- Imugene secured firm commitments to raise approximately $11.1 million through a new share placement.
- The capital injection provides the clinical-stage cell therapy business with working funding extending into 2027.
- Proceeds will primarily advance clinical trials for the company's lead blood cancer treatment asset.
Imugene (ASX:IMU) secured firm commitments to raise $11.1 million via a share placement to fund its cancer clinical trials.
The capital injection follows recorded complete medical responses from the first two evaluable patients in its combination study.
“The first two evaluable patients in our concurrent BTKi combination cohort have both achieved complete responses, providing a strong early clinical signal for azer-cel in a therapeutic class worth more than US$12 billion annually,” said Imugene Managing Director and CEO Leslie Chong.
The equity raising includes a $4.1 million director allocation pending shareholder approval.
Following the announcement, the Imugene share price was unchanged at $0.095.
The clinical-stage biopharmaceutical business focuses on developing off-the-shelf cell therapies to treat various human blood cancers.
Management plans to present further pipeline readouts at major scientific conferences throughout the upcoming calendar year.
